JPRN-jRCT1080220200未知3 期
Randomized phase III trial of amrubicin vs. carboplatin plus etoposide in elderly patients with extensive-disease small-cell lung cancer
适应症
试验速览
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 70age old 至 ot applicable（—）
- 性别
- All
入选标准
- •- Extensive-disease small-cell lung cancer
- •- Aged 70 years or elder
- •- Performance status of 0-2
- •- No prior chemotherapy
- •- Prior therapy for primary lesion
- •- Pneumonitis and/or pulmonary fibrosis
- •- Active concomitant malignancy
排除标准
- 未提供
研究者
相似试验
终止
3 期
Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)Small-cell Lung CancerNCT00286169Sumitomo Pharma Co., Ltd.130
进行中（未招募）
不适用
OPSROC: Optimal therapy for women with Platinum Sensitive Ovariance Cancer.A randomised trial comparing two different chemotherapy regiments in combination with bevacizumab in women with ovarian cancer relapsing over 6 months from first line therapy.Patients with platinum-sensitive recurrent ovarian cancerMedDRA version: 17.0Level: PTClassification code 10016180Term: Fallopian tube cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-004125-24-GBGreater Glasgow Health Board654
已完成
3 期
A prospective randomized Phase III trial of carboplatin/gemcitabine/bevacizumab vs. carboplatin/pegylated liposomal doxorubicin/bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.MedDRA - 10016180 (Fallopian tube cancer)MedDRA - 10066697 (Ovarian cancer recurrent)C56C57Malignant neoplasm of ovaryMalignant neoplasm of other and unspecified female genital organsDRKS00004913AGO Research GmbH, AGO Study Group682
已完成
不适用
Phase II study of amrubicin combined with carboplatin for unresectable invasive thymoma or thymic carcinomaThymoma/Thymic carcinomaJPRN-UMIN000002619Tohoku University Hospital40
已完成
不适用
Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancerJPRN-UMIN000002618Tohoku University Hospital30